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Abstract: Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be 
challenging in some patients. Recently, the US Food and Drug Administration approved 
ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In 
this article, we review large-scale randomized clinical trials addressing the efficacy and safety 
profile of ustekinumab for the treatment of psoriatic arthritis.
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Introduction
Psoriatic arthritis (PsA) is an incapacitating seronegative arthritis that occurs in up to 
30% of patients with psoriasis.1–3 PsA is more prevalent among patients with relatively 
severe psoriasis. Risk factors for a more severe course of arthritis include initial pre-
sentation at an early age, female sex, polyarticular involvement, genetic predisposi-
tion, and radiographic signs of the disease early on.3 The following classification has 
been outlined by Moll:4 mono- and asymmetric oligoarthritis (including the classic 
involvement of the whole digit referred to as the “sausage” digit), arthritis of the distal 
interphalangeal joints, rheumatoid arthritis-like presentation, arthritis mutilans, and 
spondylitis and sacroiliitis.
In recent years, among biologic agents, TNFα inhibitors have been a mainstay 
for the treatment of PsA.5 Although these agents can remarkably improve the clinical 
manifestations of PsA and prevent radiographic joint damage,5,6 a number of patients 
fail to respond to TNFα inhibitors, experience recurrence, or develop resistance to these 
therapies. The introduction of ustekinumab and similar drugs was therefore considered 
an advancement in the management of emergent or refractory PsA. In 2008 and 2009, 
ustekinumab was approved by the European Medicines Agency (EMA) and the US 
Food and Drug Administration (FDA), respectively, for the treatment of moderate-
to-severe plaque psoriasis in adult patients. In September 2013, the EMA and FDA 
also approved ustekinumab for the treatment of PsA. In this article, we review the 
pharmacodynamics, pharmacokinetics, efficacy, and safety profile of ustekinumab 
for the management of PsA.
Pharmacodynamics and pharmacokinetics
Ustekinumab is a fully human immunoglobulin G
1
 monoclonal antibody against the 
shared p40 subunit of IL-12 and IL-23, thereby preventing IL-12 and IL-23 from binding 
to the receptor chain IL-12Rb1 to trigger downstream signaling pathways.7 The pathways 
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activated by IL-12 and IL-23 are well established, and are 
linked to the pathogenesis of psoriasis. It has been demon-
strated that dendritic cells and macrophages can overexpress 
IL-12 and IL-23 cytokines in psoriatic lesions.8 IL-12 is a 
proinflammatory cytokine involved in differentiating naïve 
T cells into T-helper (Th)-1 cells and producing IFNγ and 
TNFα.9 IL-23 enables the expansion of Th17-positive cells, 
which produce IL-17 and other cytokines.10,11 Studies support 
the fundamental role of IL-23 and Th-17 in the pathogenesis of 
psoriasis.12,13 In addition, Filer et al noted that variations in the 
IL-23 receptor and IL-12B single nucleotide polymorphisms 
are associated with susceptibility to both psoriasis and PsA.14 
Although psoriasis and PsA have been recently shown to have 
similar susceptibility loci and considerable genetic overlap,15 
it is still not clear that both conditions respond equally well 
to ustekinumab.
The pharmacokinetic properties of ustekinumab in 
human patients have been evaluated. Zhu et al reported that 
the mean values for apparent clearance, apparent volume of 
distribution, and absorption-rate constant were similar among 
PsA patients and patients with mild-to-severe psoriasis.16 
Importantly, the patient’s body weight and the levels of 
antibodies against ustekinumab significantly affected the 
pharmacokinetic properties,16 although the significance of 
antiustekinumab antibodies has not yet been determined.17 
Other variables, such as age, sex, disease duration, and 
baseline Psoriasis Area and Severity Index (PASI) score 
showed no remarkable effects on the volume of distribu-
tion or clearance values.16 Indeed, in a population-based 
pharmacokinetic analysis, there were no apparent changes 
in pharmacokinetic properties among elderly patients.7 Also, 
it has been shown that the clearance of ustekinumab was 
not changed by concurrent administration of methotrexate, 
nonsteroidal anti-inflammatory drugs, oral corticosteroids, or 
prior exposure to anti-TNFα agents in PsA patients.7
Efficacy
Multiple clinical trials have demonstrated the beneficial 
efficacy of ustekinumab in psoriasis patients. Kauffman 
et al reported that 67% of patients treated with ustekinumab 
showed a PASI 75 over the course of a 16-week Phase I 
study.18 In another Phase I study, compared to no symp-
tom improvement for the placebo group, 76% of patients 
treated with ustekinumab achieved 75% improvement in 
PASI score.19 In a Phase II dose-ranging randomized clini-
cal trial (RCT), PASI 75 was achieved by week 12 with a 
distinct dose-dependence: 52% of patients treated with a 
single 45 mg dose, 59% of patients treated with a single 
90 mg dose, 67% of patients treated with 45 mg doses every 
4 weeks, and 81% of patients treated with 90 mg doses 
every 4 weeks.20 Over the same time period, only 2% of 
placebo-treated patients achieved PASI 75. In the phase III 
PHOENIX (Psoriasis Followed by Long-Term Extension) 
1 trial with 766 patients, 67.1% of patients treated with 45 mg 
ustekinumab and 66.4% of patients treated with 90 mg usteki-
numab achieved PASI 75 after 12 weeks, whereas 3.1% of 
the placebo-treated patients achieved PASI 75.21 PHOENIX 
2 showed comparable results in 1,230 patients. PASI 75 was 
achieved in 66.7% of patients receiving ustekinumab 45 mg, 
75.7% receiving ustekinumab 90 mg, and 3.7% receiving 
placebo.22 The Phase III ACCEPT (Active Comparator 
[CNTO1275/Enbrel] Psoriasis Trial) showed PASI 75 in 
67.5% of the group treated with 45 mg ustekinumab, 73.8% 
of the group treated with 90 mg ustekinumab, and 56.8% of 
the group treated with 50 mg etanercept.23 Finally, PEARL 
(Efficacy and Safety of Ustekinumab for the Treatment of 
Moderate-to-Severe Psoriasis: A Phase III, Randomized, 
Placebo-Controlled Trial in Taiwanese and Korean Patients) 
evaluated an Asian population of psoriasis patients, and found 
PASI 75 in 67.2% of ustekinumab-treated patients, compared 
to only 5.0% of placebo-treated patients.24
Thus far, there have been no Phase I clinical trials inves-
tigating the dose response or safety profile of ustekinumab 
for treating PsA. Support for conducting later-stage clinical 
trials for PsA efficacy was based on Phase I evidence for 
efficacy reported from clinical trials for the treatment of 
moderate-to-severe plaque psoriasis.17,18 One Phase II25 and 
two Phase III26,27 large-scale RCTs investigated the efficacy 
and safety of ustekinumab in the management of PsA. The 
results of these trials were published recently, and are sum-
marized in Table 1.
The first study was a randomized, multicenter, double-
blind, placebo-controlled, crossover Phase II trial that was 
published in 2009.25 In this study, 146 patients with active 
PsA were recruited at multiple clinical sites in Europe and 
North America, with inclusion criteria consisting of three or 
more swollen joints, three or more tender joints, and either 
a C-reactive protein (CRP) level of at least 15 mg/L or a 
minimum of 45 minutes of daily morning stiffness. Patients 
were also required to have at least one active skin psoriatic 
lesion of 2 cm or larger. Patients were randomly assigned 
to two treatment groups. Patients in the first group received 
weekly subcutaneous ustekinumab (90 or 63 mg) for 4 weeks, 
followed by placebo at weeks 12 and 16, and patients in the 
second group received placebo every week for 4 weeks, 
followed by ustekinumab (63 mg) at weeks 12 and 16. 
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An American College of Rheumatology (ACR) 20 response 
(20% or greater improvement in arthritis28) at week 12 was 
defined as the primary end point of the study. 
After 12 weeks, ACR 20 was observed in 42.1% of usteki-
numab treated patients versus 14.3% of patients who received 
placebo. At week 36, 34% of patients in the ustekinumab-
treated group, who had not received the drug for 33 weeks, 
still showed ACR 20. ACR 20 was also observed in 51% 
(week 24), 45% (week 28), and 42% (week 36) of patients 
treated with placebo followed by ustekinumab. ACR 50 and 
ACR 70 were achieved in 25% and 11% of ustekinumab-
treated patients, compared to 7% and 0 in the placebo group, 
respectively. Additionally, the ustekinumab group showed 
a significantly larger decrease from baseline in the Health 
Assessment Questionnaire Disability Index (HAQ-DI) than 
the placebo group at week 12 (-0.25 [interquartile range 
-0.50 to 0] versus 0 [interquartile range -0.25 to 0.13], 
respectively).
Moreover, PASI scores were assessed in patients 
with psoriatic lesions affecting 3% or more of their body 
surface area. At week 12, PASI 75 was achieved in 52% 
of the ustekinumab-treated group and 5% of the placebo-
treated group. Among this cohort of patients, Dermatology 
Life Quality Index (DLQI) data showed a significantly 
greater median decrease from baseline in ustekinumab-
treated patients than in placebo-treated patients at 
week 12 (-6.0 [interquartile range -14.0 to -3.0] versus 0 
[interquartile range -4.0 to 2.0], respectively). This study 
Table 1 A summary of the main outcomes presented in Phase II and III trials comparing ustekinumab to placebo
Outcome 
measure
Study Concurrent 
therapy
Treatment groups P-values
Placebo Ustekinumab  
63 or 90 mg
ACR 20 
response
Gottlieb et al25 All patients 32/76 (42%) 10/70 (14%) 0.0002
Placebo Ustekinumab  
45 mg
Ustekinumab  
90 mg
Combined  
ustekinumab
McInnes et al26 All patients 47/206 (22.8%) 87/205 (42.4%) 101/204 (49.5%) 188/409 (46.0%) ,0.0001 for all comparisons 
versus placebo
with MTX 
treatment
25/96 (26.0%) 43/99 (43.4%) 46/101 (45.5%) 89/200 (44.5%)
without MTX 
treatment
22/110 (20.0%) 44/106 (41.5%) 55/103 (53.4%) 99/209 (47.4%)
Ritchlin et al27 All patients 21/104 (20.2%) 45/103 (43.7%) 46/105 (43.8%) 91/208 (43.8%) ,0.001 for all comparisons 
versus placebo
with MTX 
treatment
14/49 (28.6%) 27/54 (50.0%) 21/52 (40.4%) 48/106 (45.3%)
without MTX 
treatment
7/55 (12.7%) 18/49 (36.7%) 25/53 (47.2%) 43/102 (42.2%)
Placebo Ustekinumab  
63 or 90 mg
PASI 75 
response
Gottlieb et al25 All patients 3/55 (5%) 33/63 (52%) ,0.0001
Placebo Ustekinumab  
45 mg
Ustekinumab  
90 mg
Combined  
ustekinumab
McInnes et al26 All patients 16/146 (11.0%) 83/145 (57.2%) 93/149 (62.4%) 176/294 (59.9%) ,0.0001 for all comparisons 
versus placebo
with MTX 
treatment
10/66 (15.2%) 32/66 (48.5%) 38/69 (55.1%) 70/135 (51.9%)
without MTX 
treatment
6/80 (7.5%) 51/79 (64.6%) 55/80 (68.8%) 106/159 (66.7%)
Ritchlin et al27 All patients 4/80 (5.0%) 41/80 (51.3%) 45/81 (55.6%) 86/161 (53.4%) ,0.001 for all comparisons 
versus placebo
with MTX 
treatment
3/29 (10.3%) 19/39 (48.7%) 22/39 (56.4%) 41/78 (52.6%)
without MTX 
treatment
1/51 (2.0%) 22/41 (53.7%) 23/42 (54.8%) 45/83 (54.2%)
Abbreviations: ACR, American College of Rheumatology; PASI, Psoriasis Area and Severity Index; MTX, methotrexate.
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demonstrated the superior efficacy of ustekinumab compared 
to placebo in improving the signs and symptoms of PsA as 
well as skin psoriatic lesions.
The two Phase III studies for PsA treatment – PSUMMIT 
(Study of the Safety and Effectiveness of Ustekinumab in 
Patients with Psoriatic Arthritis) 126 and PSUMMIT 227 – were 
multicenter, randomized, double-blind, placebo-controlled 
trials that assessed the efficacy and safety of ustekinumab 
in large populations of PsA patients.
In PSUMMIT 1, 1,174 patients were screened, and 
615 eligible patients with active PsA were randomly assigned 
to treatment groups. The patient population was from 14 coun-
tries in North America, Europe, and the Asia-Pacific region. 
The patients were included if they had at least five swollen 
joints, at least five tender joints, CRP $3 mg/L, and an active 
or past history of plaque psoriasis. Patients were randomly 
grouped to receive either subcutaneous ustekinumab 45 mg, 
subcutaneous ustekinumab 90 mg, or placebo at weeks 0 and 4, 
and every 12 weeks thereafter. Patients were evaluated at 
week 16, and those with less than 5% improvement in tender 
and swollen joint count were switched to another treatment 
arm: patients receiving placebo entered the ustekinumab 
45 mg group, and patients treated with ustekinumab 45 mg 
entered the ustekinumab 90 mg group. Finally, all patients 
who remained in the placebo group received ustekinumab 
45 mg at weeks 24 and 28, and then every 12 weeks thereafter. 
The primary end point of the study was defined as ACR 20 at 
week 24. The secondary end points at week 24 were ACR 50 
and ACR 70, PASI 75, 28-joint Disease Activity Score based 
on CRP (DAS28-CRP), Bath Ankylosing Spondylitis Disease 
 Activity Index (BASDAI), HAQ-DI, 36-item Short-Form 
Health  Survey (SF-36), and DLQI scores.
The patients in the ustekinumab 45 mg group and 90 mg 
group had significantly higher rates of ACR 20 response 
(42.4% and 49.5%, respectively) than the patients in the 
placebo group (22.8%) at week 24. The authors also reported 
significant differences at week 24 for ACR 50. An ACR 50 
response was achieved in 24.9% of patients in the usteki-
numab 45 mg group, 27.9% of patients in the ustekinumab 
90 mg group, and 8.7% of patients in the placebo group 
(P,0.0001 for all ustekinumab versus placebo  comparisons). 
The same trend was observed for ACR 70: 12.2% of usteki-
numab 45 mg patients, 14.2% of ustekinumab 90 mg patients, 
and 2.4% of placebo patients (P=0.0001 for 45 mg group ver-
sus placebo, and P,0.0001 for 90 mg group versus placebo). 
While only 11.0% of patients in the placebo-treated group 
had a PASI 75 response, 57.2% and 62.4% of patients in the 
45 mg and 90 mg ustekinumab groups achieved a PASI 75 
response. Notably, the results were irrespective of concurrent 
methotrexate therapy. Additionally, ustekinumab appeared 
to be more efficacious than placebo when DAS28-CRP, 
BASDAI 20, and quality-of-life measures such as HAQ-DI, 
SF-36, and DLQI were taken into consideration. PSUMMIT 1 
also reported clinically important and statistically significant 
results regarding the effect of ustekinumab on patients with 
enthesitis or dactylitis. At week 24, enthesitis was present in 
68.6% and 60.8% of patients in the ustekinumab 45 mg and 
90 mg groups, respectively, compared to 81.0% of patients in 
the placebo group. Similar results were noted when patients 
were examined for dactylitis (56.6%, 55.8%, and 76.1%, 
respectively). At present, TNFα blockers are the only FDA-
approved drugs for these conditions. The promising efficacy 
of ustekinumab on dactylitis and enthesitis in addition to 
spondyloarthritis may provide a further therapeutic option 
for these patients.29
Ustekinumab also showed an efficacious effect in placebo-
treated patients after switching to ustekinumab. Among 
120 patients that began receiving ustekinumab at week 24, 
ACR 20 scores were achieved in 65.2% by week 52, a compa-
rable result to the other treatment groups. Similarly, PASI 75 
response was reached in 67.7% of patients in the placebo 
group that crossed over at week 24, compared to 68.1% of 
patients in the ustekinumab 90 mg group (P.0.05). Other 
outcome measures, such as ACR 50, ACR 70, quality-of-life 
measures, and skin indices, showed the same trend at week 52. 
It is important to consider the fact that this trial was not 
placebo-controlled beyond 24 weeks. Therefore, the results 
beyond this time point should be interpreted cautiously.
In PSUMMIT 2, 312 patients with PsA were randomly 
assigned to be treated with 45 mg or 90 mg ustekinumab 
or a placebo. Patients were randomized using a stratified 
central randomization method. Similar to PSUMMIT 1, 
the treatments occurred at weeks 0, 4, and every 12 weeks 
thereafter. The PsA patients were required to have active 
PsA for at least 6 months. The eligible patients on other 
treatments also had a minimum refractory period to other 
treatments, including disease-modifying antirheumatic drugs, 
(3 months), non-steroidal anti-inflammatory drugs (4 weeks), 
etanercept, adalimumab, golimumab, or certolizumab pegol 
(8 weeks), or infliximab or other TNF antagonists (14 weeks). 
Concurrent methotrexate therapy was allowed if started more 
than 3 months before commencement of the trial and if at a 
stable dose of #25 mg/week for at least 4 weeks. Patients who 
had less than 5% improvement in their joint symptoms entered 
a “blinded early escape” at week 16. This protocol involved 
patients receiving placebo switching to ustekinumab 45 mg, 
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those receiving ustekinumab 45 mg switching to ustekinumab 
90 mg, and patients receiving ustekinumab 90 mg continuing 
with blinded 90 mg dosing. Placebo-treated patients who did 
not start the early escape crossed over to receive ustekinumab 
45 mg at week 24 and thereafter. The primary end point of this 
trial was the same as for PSUMMIT 1, and included ACR 20 at 
week 24. Other end points included PASI score, DAS28-CRP 
less than 2.6, DLQI, SF-36, 0.3 or more unit improvement in 
HAQ-DI, presence of dactylitis, entheseal tenderness or pain 
using the PsA-modified Maastricht Ankylosing Spondylitis 
Enthesitis Score 24, BASDAI, and level of fatigue using the 
13-item Functional Assessment of Chronic Illness Therapy – 
Fatigue (FACIT-Fatigue) questionnaire.
The ACR 20 response for PSUMMIT 2 at week 24 was 
very similar in the 45 mg and the 90 mg ustekinumab groups 
(43.7% and 43.8%, respectively). Both doses achieved a sig-
nificantly higher response rate when compared to the placebo 
group (20.2%, P,0.001 compared to either ustekinumab-
treatment groups). The number of patients who achieved 
DAS28-CRP response was comparable in both of the usteki-
numab groups, with a cumulative response of 53.8%, and 
both were significantly higher than the placebo group, with a 
29.8% response. PASI 75 response was achieved in a higher 
proportion of the ustekinumab-treated than placebo-treated 
patients at week 24, and all comparisons showed statistically 
significant efficacy (Table 1), irrespective of the status of 
methotrexate therapy or body weight. All the quality-of-
life measures (HAQ-DI score, FACIT-Fatigue score, DLQI 
score, and SF-36 score) were significantly improved in both 
ustekinumab groups versus the placebo group, except the 
mental component of SF-36, which was comparable between 
all groups at week 24. Patients with enthesitis and dactylitis 
responded better to both ustekinumab groups than the placebo 
group. However, this improvement only reached statistical 
significance in patients with enthesitis.
Among those patients who received methotrexate, an ACR 
20 response was achieved at week 24 in 35.6% of patients in the 
combined ustekinumab groups versus 14.5% of patients in the 
placebo group (P,0.01). The PASI 75 response was even more 
apparent in the combined ustekinumab groups compared to the 
placebo group among the same subgroup of patients (47.1% 
versus 2.0%, P,0.01). Among patients who were on TNFα 
inhibitors, median changes in HAQ-DI scores were significantly 
more pronounced (-0.13, interquartile range -0.38 to 0) in 
the combined ustekinumab groups than the placebo-treatment 
group (0, interquartile range -0.13 to 0.13) (P,0.05).
In a recent updated report of PSUMMIT 1 and 
 PSUMMIT 2, Kavanaugh et al showed that both 
ustekinumab 45 mg and ustekinumab 90 mg can provide a 
sustained inhibition of radiographic progression of joint dam-
age, and this effect was significantly higher than the placebo 
group. The PsA-modified van der Heijde–Sharp score was 
used to evaluate hand or foot radiographs to monitor the 
progression of joint involvement. The placebo group had a 
significantly higher average score (1.0±3.9) at week 24 when 
compared to the ustekinumab 45 mg (0.4±2.1) and 90 mg 
groups (0.4±2.4).30
Safety
The safety profile of ustekinumab has been extensively 
examined for the treatment of psoriasis as well as PsA. The 
Phase III multicenter PSUMMIT 1, which administered treat-
ment of 45 mg ustekinumab, 90 mg ustekinumab, or placebo 
for 52 weeks, demonstrated a 42% rate by week 16 and 49.5% 
by week 24 of at least one adverse event (AE) occurring in 
the combined ustekinumab-treatment groups.26 The most 
common AEs of the combined ustekinumab-treatment groups 
for psoriasis were respiratory tract infections, headaches, 
arthralgia, and nasopharyngitis. There was a combined 1.7% 
rate of serious AEs, with consequent discontinuation of treat-
ment in six patients.26
In a randomized clinical study of 146 patients with PsA 
treated with ustekinumab, the treatment was reasonably well 
tolerated.25 Patients were administered a 63 mg or 90 mg 
dose of ustekinumab or a placebo. By 12 weeks of treatment, 
61% of the patients in the combined treatment groups and 
63% of the patients in the placebo group had one or more 
AEs, suggesting that ustekinumab was well tolerated com-
pared to placebo. By week 36, the treatment group had 76% 
of participants with an AE compared to 63% of the patients 
treated with placebo followed by ustekinumab.25 Similar to 
ustekinumab treatment for psoriasis, the majority of AEs 
were upper respiratory tract infections or nasopharyngitis.
In PSUMMIT 1, 615 adult PsA patients were random-
ized to receive 45 mg/90 mg/placebo treatment and were 
followed for 2 years.31 The placebo-treated patients began 
45 mg ustekinumab therapy at week 24. A total of 490 of the 
participants completed the study, with 5% of the participants 
discontinuing due to serious AEs. The rates (per 100 patient-
years of follow-up) of serious infections, malignancies, and 
major adverse cardiovascular events were 1.23, 0.38, and 
0.66, respectively, in the ustekinumab-treated groups when 
combined.31
In PSUMMIT 2, with 312 patients with PsA, usteki-
numab was administered at doses of 45 mg or 90 mg or 
a placebo, with the placebo group crossing over to 45 mg 
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ustekinumab at 24 weeks.27 After 16 weeks of treatment, 
the combined ustekinumab-treatment group had AEs in 
61.8% of the patient population compared to 54.8% in 
the placebo group. These data suggest that ustekinumab is 
reasonably well tolerated. Even at 24 weeks, the combined 
ustekinumab group showed 66.4% of the patients having an 
AE compared to 63.5% for the placebo group.27 The majority 
of AEs were similar to those found in psoriatic patients, 
with nasopharyngitis and upper respiratory tract infections 
as the most common.
A study aggregating the results from a Phase II study,25 
PSUMMIT 1, and PSUMMIT 2 results included 1,071 
treated patients with PsA.32 The placebo-treated group had 
348.07 AEs per 100 patient-years compared to 375.83 for 
ustekinumab-treated patients in the PsA-specific studies. 
Furthermore, the placebo group had 12.69 serious AEs 
compared to 5.75 for the ustekinumab-treated group per 
100 patient-years. Results from psoriasis studies with PsA 
patient subgroups reported similar levels of AEs of 476.42 for 
the placebo and 481.31 for the ustekinumab-treated groups 
(events per 100 patient-years).32
Aggregated data from a Phase II study,20 PHOENIX 1, 
PHOENIX 2, and ACCEPT included 3,117 patients totaling 
8,998 patient years of follow-up and compared the safety of 
ustekinumab 45 mg or 90 mg treatment in psoriatic patients 
to the PsA subgroup.33 Of the 858 patients with PsA totaling 
2,490 years of patient follow-up, there were 249.40 AEs per 
100 patient-years compared to 232.59 AEs per 100 patient-
years for the overall population. Among the AEs, the rate 
of major adverse cardiovascular events and serious infec-
tions for the PsA group was 0.56/100 patient-years and 
1.53/100 patient-years compared to 0.44/100 patient-years 
and 1.10/100 patient-years in the overall population.33 
Therefore, ustekinumab treatment for PsA appears to 
have comparable results to the overall treated psoriasis 
population.
There has been extensive research on the safety profile 
of ustekinumab for the treatment of psoriasis and PsA, and it 
appears that long-term treatment with ustekinumab does not 
alter the risks associated with its use. Furthermore, there are 
no dose-dependent risks associated with ustekinumab use. 
The safety of ustekinumab is comparable to other approved 
drugs for the treatment of psoriasis and PsA.
Conclusion
The current literature supports the efficacy and safety of 
ustekinumab in the treatment of PsA. The results from 
Phase III trials suggest that ustekinumab is also useful 
for treating enthesitis, dactylitis, and spondyloarthrosis. 
 Furthermore, data from the PSUMMIT trials suggest that 
the onset of action is slower with ustekinumab than TNFα 
inhibitors, although a similar efficacy rate can be achieved by 
52 weeks. Future trials comparing these two classes of drugs 
are essential to further elucidate their relative efficacy.29
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